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In many countries, specialist cancer services are centralised to improve outcomes. We explored how centralisation affects the
radical treatment of high-risk and locally advanced prostate cancer in the English NHS. 79,085 patients diagnosed with high-risk
and locally advanced prostate cancer in England (April 2014 to March 2016) were identiﬁed in the National Prostate Cancer Audit
database. Poisson models were used to estimate risk ratios (RR) for undergoing radical treatment by whether men were
diagnosed at a regional co-ordinating centre (‘hub’), for having surgery by the presence of surgical services on-site, and for
receiving high dose-rate brachytherapy (HDR-BT) in addition to external beam radiotherapy by its regional availability. Men were
equally likely to receive radical treatment, irrespective of whether they were diagnosed in a hub (RR 0.99, 95% CI 0.91–1.08).
Men were more likely to have surgery if they were diagnosed at a hospital with surgical services on site (RR 1.24, 1.10–1.40),
and more likely to receive additional HDR-BT if they were diagnosed at a hospital with direct regional access to this service
(RR 6.16, 2.94–12.92). Centralisation of specialist cancer services does not affect whether men receive radical treatment, but it
does affect treatment modality. Centralisation may have a negative impact on access to speciﬁc treatment modalities.
Introduction
Approximately one third of all men with a new diagnosis of
prostate cancer in England have locally advanced disease.1
These men have a high risk of disease progression and cancer-
related mortality, highlighting the importance of radical treat-
ment in this group.2,3 Contemporary data from the National
Prostate Cancer Audit (NPCA) suggest that 27% of men with
high-risk or locally advanced prostate cancer do not receive
radical treatment with surgery or radiotherapy.4 According to
the NPCA1 and the National Institute for Health and Care
Excellence5 risk stratiﬁcation, high-risk localised disease is clas-
siﬁed in the same group as ‘locally advanced’ disease.
There is a clear survival beneﬁt for the combination of exter-
nal beam radiation therapy (EBRT) and androgen deprivation
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therapy (ADT), over either treatment alone, and this combi-
nation is a standard of care for men with locally advanced
prostate cancer.6–8 Current UK National Institute for Health
and Care Excellence (NICE) guidelines (2014) and European
Association of Urology (EAU) guidelines (2017) also recom-
mend combining high-dose rate brachytherapy (HDR-BT)
with EBRT, for suitable men with high-risk prostate cancer.5,9
Recently reported observational data are now beginning to
favour combination therapy in terms of disease progression
and mortality but utilisation of this treatment strategy has not
been previously reported in England.10
Radical prostatectomy (RP) has historically been reserved for
clinically localised disease but there is increasing evidence that it
has a positive effect in high-risk men, and even in more advanced
cases.11 It is currently used in 22% of men with high-risk or
locally advanced patients in England (2015/16).4 Optimal use of
RP as part of a multimodal approach is yet to be established but
current guidelines advocate its use for selected patients.12
For over a decade, specialist radiotherapy and radical pros-
tatectomy services for prostate cancer have been centralised in
England, which has restricted the number of centres providing
these specialist services and in turn increased the centres’
average volume of procedures. The rationale for this centrali-
sation is to optimise the quality of care men receive and to
improve patient outcomes by focussing treatment in high-
volume centres.13,14 To co-ordinate access to these specialist
services 48 specialist Multi-Disciplinary Teams (MDT) were
set up across England. Each specialist MDT is made up of a
regional referral network of hospitals within a speciﬁc geo-
graphical area of the country. Hospitals assigned as the lead of
each regional referral network, or ‘hub’ site, act as regional co-
ordinating centres. Each hub is usually a specialist centre for
either radiotherapy, surgery or both and the other hospitals
within the network act as ‘spoke’ hospitals. Most spoke hospi-
tals are non-specialist centres and therefore have to refer to
specialist centres for radical treatment, but a few provide one
or more treatment modalities on-site.
The NPCA collected information regarding the organisa-
tion of prostate cancer services for each regional referral net-
work and the specialist treatment services available on-site at
each hospital.15 Between April 2014 and March 2016, 138 hos-
pitals in the English National Health Service (NHS) provided
diagnostic facilities for prostate cancer, of which 53 were
specialist surgical centres, 51 were specialist radiotherapy
centres and 19 were specialist HDR-BT centres. Access to
radiotherapy and surgical centres is available to every hospi-
tal within England via one of the 48 regional referral net-
works, however HDR-BT services are only available to
hospitals within 24 of these regions, either directly or exter-
nally via a neighbouring regional referral network. HDR-BT
has therefore become a super-specialised treatment modality
within the complex, centralised system for prostate cancer
care in England.
The hub-and-spoke model for prostate cancer care aims to
improve outcomes while aiming to guarantee appropriate
access, irrespective of the hospital where a patient is diag-
nosed. Despite this, studies have started to emerge highlight-
ing that this centralisation process has led to an inequity of
access to surgery in the treatment of other cancers, such as
lung cancer and liver metastases in colorectal cancer.15–17
We therefore aim to assess whether cancer service centrali-
sation impacts on the access to radical treatment, or on the
speciﬁc type of radical treatment that men with high-risk and
locally advanced prostate cancer receive in the English NHS.
Materials and Methods
Study population
The NPCA is a national clinical audit assessing the quality of
services and care provided to men with prostate cancer in
England and Wales. The NPCA has been reporting about the
treatment and outcomes of all patients newly diagnosed with
prostate cancer since April 2014.
All patients newly diagnosed with prostate cancer between
April 1st 2014 and March 31st 2016 were identiﬁed in the
NPCA database. This database includes relevant data items
from the English Cancer Registry and data items speciﬁc to
the NPCA, both supplied by Public Health England’s National
Cancer Registration and Analysis Service (NCRAS). Disease
status was assigned according to a risk stratiﬁcation algorithm
previously described by the NPCA1, and based on the NICE
criteria5, which uses NPCA data items for each cancer charac-
teristic (Gleason score, PSA and TNM). TNM data used pref-
erentially clinical cancer registry items and then pathological
cancer registry items, in line with the Union for International
Cancer Control (UICC) TNM 7th edition, taking staging
information that was updated as much as possible by cancer
registry staff. Gleason scores were based on prostate biopsy
information. The patient cohort was restricted only to men
with non-metastatic, high-risk or locally advanced disease
What’s new?
More than one-quarter of men with high-risk or locally advanced prostate cancer in England do not receive radical treatment
with radiotherapy or surgery, potentially owing to differences in treatment access. Here, prostate cancer service centralisation
in England was investigated for potential impacts on treatment access. Among English patients in the National Prostate Cancer
Audit database, centralisation had no impact on decisions to use radical treatment. It did, however, affect treatment option
availability, with potential consequences for patient outcome. Patients were more likely to undergo surgery or high dose-rate
brachytherapy when diagnosed at hospitals with direct links to these services.
2 Impact of prostate cancer service centralisation
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deﬁned as any one of: Gleason score ≥ 8, PSA > 20 ng/mL or
T3/T4 (N1).
The NPCA database was linked at patient-level with two
routine databases. Hospital Episode Statistics (HES) is a data-
base of all hospital admissions in the English NHS and is a
source of surgery-speciﬁc information about operation type
and date.18 The National Radiotherapy Data Set (RTDS) is a
national database that contains standardised data from all
NHS hospital providers of radiotherapy services in England.19
1495 men without a documented diagnosing hospital were
excluded.
Baseline characteristics
English Cancer Registry data was used to identify the diagnos-
ing hospital, the date of diagnosis, cancer characteristics, eth-
nicity and age at diagnosis for each man. Cancer
characteristics were used for stratifying disease status but also
to provide baseline information.
The Royal College of Surgeons (RCS) Charlson score was
used to identify co-morbid conditions in the HES record
based on co-morbidities that were recorded one year before a
patient’s prostate cancer diagnosis.20 The Index of Multiple
Deprivation (IMD) was used to categorise patients into ﬁve
socioeconomic groups (1 = least deprived; 5 = most deprived)
based on the areas in which they lived. The IMD ranks 32,482
areas, and each area covers a mean population of around 1500
people or 400 households. The ﬁve categories were ﬁfths of
the national IMD ranking of these areas.21
Outcome variables
The OPCS Classiﬁcation of Interventions and Procedures
(OPCS-4) code ‘M61’ was used to identify the men in the
HES record who underwent an RP and the date of their oper-
ation.22 The RTDS data item ‘treatment modality’ was used to
select men who underwent EBRT and/or brachytherapy and
the date of their treatment. Brachytherapy dosing information
was used to identify the men who received HDR-BT.
Three binary outcome measures were used. The ﬁrst was
whether men with high-risk or locally advanced prostate can-
cer received any radical treatment (EBRT, brachytherapy, RP
or a combination) within one year of diagnosis. The second
was whether surgery was selected for the men who received
radical treatment. The third was whether HDR-BT was pro-
vided for the men who received radiotherapy. Radical treat-
ment was deﬁned as the ﬁrst treatment selected and therefore
men receiving additional salvage treatment were included
within the group according to their primary treatment.
Exposure variables
One key aim of the NPCA was to assess the conﬁguration and
availability of specialist prostate cancer services in England. In
2014, the NPCA undertook an organisational survey of all
NHS hospitals across England. Questionnaires established the
availability and location of core diagnostic, treatment and
support services for the management of non-metastatic pros-
tate cancer. The survey was updated in December 2016 to
reﬂect changing service organisation.
This organisational survey was used to provide information
about available services at each hospital with regards to RP,
EBRT and HDR-BT, as well as other services. Binary variables
were created to express the hub or spoke status of each diag-
nosing hospital, the provision of RP services on-site at each
diagnosing hospital, and the availability of HDR-BT services
in each regional referral network. These three variables were
the main exposure variables for our study.
Statistical analysis
Multivariable multilevel Poisson regression, with robust stan-
dard errors, was used to estimate the risk ratio of receiving
radical treatment by whether men were diagnosed at a hub or
spoke hospital, adjusted for age, ethnicity, socioeconomic dep-
rivation status, Charlson score, T-stage, N-stage, Gleason
score and PSA value.23 A random intercept was modelled for
each hospital to adjust for clustering within hospitals.24
A second regression model was performed for a cohort of
men who received radical treatment to estimate the likelihood
of receiving RP according to whether surgery was available
on-site at the diagnosing hospital. A ﬁnal regression model
was performed for a cohort of men who received radiotherapy
to estimate the likelihood of receiving HDR-BT according to
whether these services were regionally available.
Missing data for ethnicity (6.6%), Charlson score (8.0%),
T-stage (1.6%), N-stage (6.7%), Gleason score (26.3%) and
PSA (19.9%) were imputed with statistical imputation
using chained equations to create ten data sets. Rubin’s rules
were then used to combine the risk ratios across all ten
data sets.
Results
79,085 newly diagnosed patients were identiﬁed from the
NPCA database between April 1st 2014 and March 31st 2016.
1495 men (1.9%) and 7840 men (9.9%) were excluded as there
was insufﬁcient information available to ascertain their diag-
nosing hospital or cancer stage, respectively. The patient
cohort was further restricted to a ﬁnal cohort of 27,248 men
(48.8%) with high-risk or locally advanced prostate can-
cer (Fig. 1).
Most men (56.3%) were diagnosed at a spoke hospital
(Table 1). There was no signiﬁcant difference in the character-
istics of those diagnosed at a hub or spoke hospital (age,
ethnicity, socioeconomic deprivation status, number of co-
morbidities, T stage, N stage, Gleason score and PSA).
66% of the men received radical treatment for their high-
risk or locally advanced disease (Table 2). The variation
between the 48 regional referral networks that co-ordinate
specialist prostate cancer services ranged from 43.4% to
84.9%. Radical treatment was performed just as frequently,
irrespective of whether the diagnosing hospital was a hub or a
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spoke: 8051 of 11,895 men (67.7%) who were diagnosed at a
hub hospital received radical treatment, compared to 9941 of
15,353 (64.8%) who were diagnosed elsewhere (adjusted risk
ratio 0.99, 95% CI 0.91 to 1.08).
Men with high-risk or locally advanced disease were less
likely to receive radical treatment if they had one or more
comorbidity, T1 or T4 stage, lymph node involvement, Glea-
son score 6, PSA >20 ng/mL, or were aged 70 years or more
(p always <0.05), but there was no evidence for an association
with ethnicity (Supporting Information Table 1). Although
there was a trend toward decreasing socioeconomic depriva-
tion and receipt of radical treatment, this did not reach statis-
tical signiﬁcance (p = 0.07).
Of the 17,992 men who received radical treatment, 5116
(28.4%) underwent surgery. RP was performed more frequently
for men who were diagnosed at a hospital which provided surgical
services: Of the 9199 men who were diagnosed at a hospital with
these services available on-site, 2946 (32.0%) had an RP, compared
to 2170 (24.7%) of the 8793 patient who were diagnosed elsewhere
(adjusted risk ratio 1.24, 95% CI 1.10 to 1.40) (Table 3). Men were
more likely to receive surgery as radical treatment if they had a co-
morbidity score ≤ 1, T2 or T3 stage, absent lymph node involve-
ment, Gleason score ≤ 7, PSA <10 ng/mL, a lower socioeconomic
deprivation score or were younger (p always <0.05). There was no
evidence for an association between ethnicity and having surgery
(Supporting Information Table 2).
Figure 1. Flow-chart of all men with a new diagnosis of prostate cancer in England from April 1, 2014 to March 31, 2016 and how they were
managed.
4 Impact of prostate cancer service centralisation
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35 men (5.8%) who underwent brachytherapy were
excluded as there was insufﬁcient information to differentiate
between HDR-BT and low-dose rate brachytherapy (LDR-
BT). Of the 12,841 men who received radiotherapy and could
potentially be included, 556 (4.4%) underwent HDR-BT.
HDR-BT was used more frequently in men who were diag-
nosed at a hospital with regional access to these services:
490 (7.7%) of the 6390 men had regional access to HDR-BT,
compared to 76 (1.2%) of the 6451 men diagnosed in hospi-
tals without regional access (adjusted risk ratio 6.16, 95% CI
Table 1. Patient and tumour characteristics of men with high-risk and locally advanced prostate cancer according to whether they were
diagnosed at a hub or a spoke hospital.1
Hub
n = 11,895
Spoke
n = 15,353
All men
N = 27,248
n % n % N %
Age group (years)
<65 2,571 21.6 3,038 19.8 5,609 20.6
65–70 2,703 22.7 3,333 21.7 6,036 22.2
70–75 2,625 22.1 3,287 21.4 5,912 21.7
>75 3,996 33.6 5,695 37.1 9,691 35.6
Ethnicity
White 10,291 92.9 13,476 93.7 23,767 93.4
Black 383 3.5 419 2.9 802 3.2
Other 399 3.6 491 3.4 890 3.5
Missing 822 967 1,789
Socioeconomic deprivation status (fifth of national distribution)
1 (least deprived) 1,651 13.9 1,858 12.1 3,509 12.9
2 1,921 16.2 2,649 17.3 4,570 16.8
3 2,386 20.1 3,273 21.3 5,659 20.8
4 2,889 24.3 3,863 25.2 6,752 24.8
5 (most deprived) 3,048 25.6 3,710 24.2 6,758 24.8
Number of co-morbidities (RCS Charlson score)
0 8,049 75.0 10,305 71.9 18,354 73.2
1 1,911 17.8 2,805 19.6 4,716 18.8
≥2 781 7.3 1,220 8.5 2,001 8.0
Missing 1,154 1,023 2,177
T stage
1 587 5.0 837 5.5 1,424 5.3
2 2,737 23.4 3,662 24.2 6,399 23.9
3 7,873 67.3 9,918 65.6 17,791 66.4
4 507 4.3 692 4.6 1,199 4.5
Missing 191 244 435
N stage
0 9,659 87.9 12,595 87.2 22,254 87.5
1 1,329 12.1 1,846 12.8 3,175 12.5
Missing 907 912 1,819
Gleason score
6 613 7.3 1,170 10.1 1,783 8.9
7 3,900 46.1 5,143 44.3 9,043 45.0
≥8 3,944 46.6 5,306 45.7 9,250 46.1
Missing 3,438 3,734 7,172
Serum PSA (ng/mL)
<10 2,756 30.7 3,767 29.3 6,523 29.9
10–20 2,249 25.0 3,094 24.1 5,343 24.5
>20 3,982 44.3 5,983 46.6 9,965 45.7
Missing 2,908 2,509 5,417
1Hub: hospital assigned as the lead of a regional referral network. Spoke: peripheral hospitals within the regional referral network.
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2.94 to 12.92) (Table 4). Men were more likely to receive both
HDR-BT and EBRT, over EBRT alone, if they had a
co-morbidity score ≤ 1, ≤T3 stage, absent lymph node
involvement, Gleason score ≤ 7, PSA 10 ng/mL to 20 ng/mL
(compared to PSA >20 ng/mL), a lower socioeconomic depri-
vation score or were younger (p < 0.05 for all variables). There
was no association between ethnicity or Gleason score and the
receipt of HDR-BT (Supporting Information Table 3).
Discussion
The centralisation of prostate cancer services at hubs and the
use of regional referral networks in England does not impact
on the overall access to radical treatment for men with high-
risk/locally advanced prostate cancer. However, there is varia-
tion between centres in the type of treatment selected. Men
diagnosed at a hospital with surgical facilities were more likely
to receive surgery than men diagnosed at a non-surgical cen-
tre. Equally, men diagnosed at a hospital where HDR-BT was
regionally available were more likely to receive it.
Treatment practices
Our data indicates that between April 2014 and March 2016,
34% of men with high-risk or locally advanced prostate cancer
did not receive radical treatment and were potentially under-
treated. Latest ﬁgures show that this ﬁgure continues to drop
(27% in men diagnosed between April 2016 and March 2017)
but in general these men represent older and more co-morbid
or frail patients where radical treatment is contraindicated.4
These observations are generally consistent with other devel-
oped countries where rates of under-treatment are reported at
32% in France (2011)25, 41% in Germany (2004 to 2012)26
and 15% in the US (2004 to 2013).26,27
EBRT remains the most common primary treatment
modality in the UK for the treatment of high-risk or locally
advanced prostate cancer (47% had EBRT and 19% surgery).
These ﬁgures are consistent with the most recent NPCA data
(2015/2016) where 49% had EBRT and 22% had surgery.4
There is currently no clear evidence in favour of using pri-
mary RP for these cases but observations from other high-
income countries indicate that RP is used more frequently for
this patient group (RP 43% and EBRT 42% in the US; RP
37% and EBRT 22% in Germany).26 Comparisons are difﬁcult
due to different inclusion criteria but contemporary ﬁgures all
indicate that the use of RP in high-risk and locally advanced
men is increasing, especially within a multimodal setting.26–29
Cancer service centralisation
Cancer services in the UK have been centralised to high-
volume centres in order to improve patient outcomes.13,14
Our data show that the hub-and-spoke model appears to be
working as men are equally as likely to receive radical treat-
ment, irrespective of the type of hospital where they were
diagnosed. This is in contrast to other centres’ experience in
the UK and Europe with other cancer types, where service
centralisation has had the opposite effect and led to a treat-
ment inequity between hospitals.16,17
Data from the US have shown that high-volume centres
and hospitals treating high proportions of men with newer
technologies (robotic surgery or intensity-modulated radiation
therapy) are more likely to treat men radically. Comparisons
between the UK and the US are complex however, due to
organisational differences in cancer care.30 US arrangements
are more fragmented and less centralised which allows the
type of hospital to have more of an effect on the treatment
Table 2. Results of Poisson regression analysis evaluating the association between the hub or spoke status of the diagnosing hospital and
whether radical treatment was received for men with high-risk and locally advanced prostate cancer (n = 27,248).1
Radical Treatment (%) Adjusted RR 95% CI P2
Diagnosing hospital 0.85
Hub 67.7 1
Spoke 64.8 0.99 0.91 - 1.08
1Adjusted for age, ethnicity, socioeconomic deprivation status, RCS Charlson co-morbidity score, T stage, N stage, Gleason score, and PSA.
2Wald test.
Table 4. Results of Poisson regression analysis evaluating the
association between the regional availability of high dose rate
brachytherapy (HDR-BT) services and whether men with high-risk and
locally advanced prostate cancer who received radical radiotherapy
also received HDR-BT (n = 12,835).1
HDR-BT (%) Adjusted RR 95% CI P2
HDR-BT available <0.01
No 1.2 1
Yes 7.7 6.16 2.94 - 12.92
1Adjusted for age, ethnicity, socioeconomic deprivation status, RCS Charl-
son co-morbidity score, T stage, N stage, Gleason score, and PSA.
2Wald test.
Table 3. Results of Poisson regression analysis evaluating the
association between the availability of surgical services on-site and
whether men with high-risk and locally advanced prostate cancer
who received radical treatment underwent surgery (n = 17,992).1
Surgery (%) Adjusted RR 95% CI P2
On-site surgery <0.01
No 24.7 1
Yes 32.0 1.24 1.10 - 1.40
1Adjusted for age, ethnicity, socioeconomic deprivation status, RCS Charl-
son co-morbidity score, T stage, N stage, Gleason score, and PSA.
2Wald test.
6 Impact of prostate cancer service centralisation
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men receive. In contrast, the creation of the 48 regional refer-
ral networks in the UK currently ensures consistent access to
radical treatment irrespective of hospital type. The disparity in
insurance coverage in the US also contributes to the issue of
under-treatment, a problem which is avoided in the UK due
to the beneﬁts of a universal healthcare system.30,31
Treatment selection—HDR-BT
Combining HDR-BT and EBRT for the treatment of high-risk
prostate cancer improves biochemical control over EBRT
alone, and it has been included in NICE guidelines since
2014.5,32 Randomised data is lacking regarding its survival
advantage, whereas observational data, including their colla-
tion in a meta-analysis, has suggested its superiority.10,32,33
Despite the growing evidence in support of HDR-BT for high-
risk disease, literature is lacking regarding the uptake and
availability of this modality in the UK. Only 19 hospitals in
England provide HDR-BT services and, of the 12,841 men
who underwent radiotherapy in the study period, only 4.4%
received multimodal treatment with HDR-BT.
Men were more likely to receive HDR-BT if they were
diagnosed at a hospital where it was regionally available, indi-
cating a huge disparity in treatment access. The US has seen
declining rates of brachytherapy use, with and without EBRT,
and it has been suggested that this is due to changes in refer-
ral patterns, advances with alternative therapies or the lack of
adequate training.27 These explanations highlight similarities
with our ﬁndings where the availability of HDR-BT services is
limited to only half of the regional referral networks in
England. Expansion of HDR-BT services at other radiotherapy
centres across the UK, with additional communication chan-
nels between regional referral networks, may improve access
in the future.
Treatment selection—surgery
Although service centralisation does not appear to affect
access to radical treatment, we have shown that men diag-
nosed at surgical centres were more likely to undergo radical
prostatectomy than those diagnosed elsewhere. This ﬁnding
was also observed in the US where patients seen at commu-
nity hospitals, as opposed to high-volume academic institu-
tions or cancer centres, were less likely to have surgery as
their initial treatment.27
Specialty bias is well documented where physicians and
surgeons tend to recommend treatments that they themselves
are trained to deliver. In prostate cancer, surgeons are more
likely to recommend RP than non-surgeons.34,35 This bias can
be extrapolated to sub-specialty urology whereby urologists
who are sub-specialists in pelvic oncology, and work at spe-
cialist centres, may be more likely to recommend RP for
higher risk men than generalists who adhere to the standard
of care. Specialists may be also less risk averse to operating on
more elderly patients or men with multiple co-morbidities.
Although service centralisation leads to differences in
treatment selection between hospitals, clearly this is a multi-
factorial process involving the complex interplay of patient,
clinician, hospital, geographical, socioeconomic and ﬁnancial
factors, where all factors should be taken into account as part
of the decision-making process.35
Strengths and limitations
Strengths of this population-based study include the high vol-
ume of patients included. Data on all men newly diagnosed
with prostate cancer are collected by NCRAS and so helps to
limit potential selection bias of our study cohort.
A further strength of our study is the accuracy of the rou-
tinely collected data used which has been shown to be sufﬁ-
ciently high to support its use for research.36 It was not
possible to differentiate between men who did not have radi-
cal treatment and those with missing treatment information.
However, this misclassiﬁcation is likely to be minimal, given
the coding completeness, and non-differential between com-
parator groups, given that the primary purpose of the admin-
istrative data used is for reimbursement, and would therefore
only lead to an underestimation of the effect. In addition, a
validated method was used to identify co-morbidities in the
HES record which aids the validity of our adjusted study
estimates.20
Limitations include the selection bias due to the exclusion
of men with an unknown diagnosing hospital (1.9%) or risk
group (9.9%). However, the amount of missing data was mod-
est in relation to the overall study size and we therefore feel
that the ﬁndings remain representative. A further limitation is
that because we were using available existing data there was
no information on the reasons why men did not undergo rad-
ical treatment. Factors may include patient preference, path to
diagnosis (PSA testing or symptomatic presentation), travel
times, frailty or treatment contraindications, and without
adjusting for these factors the value of the term ‘under-treat-
ment’ has to be interpreted with caution. Equally there are
important risk factors which are not routinely collected, such
as family history, and may further inﬂuence treatment
practices.
Conclusions
The centralisation of prostate cancer services does not affect
the decision to treat men with high-risk or locally advanced
prostate cancer radically. However, the provision of surgical
services or specialist HDR-BT units at speciﬁc hospitals in
England appears to cause differences in treatment selection.
Discussions within regional referral networks seem to be
focused on whether or not to offer radical treatment but the
type of treatment selected remains left to those directly
involved in the patient’s management. More speciﬁcally, the
limited regional availability of HDR-BT is likely to be prevent-
ing its selection in speciﬁc geographical areas of England.
To ensure patient-centred care, more attention should be
given to the type of treatment men receive and ensure that all
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potential options are considered when newly diagnosed men
are discussed within the specialist MDT of a regional referral
network. This is particularly relevant for ﬁt, elderly patients
where radical treatment may be a good option. Also, access to
the HDR-BT services needs to be expanded and inter-region
referral pathways established, so these services are more
widely available for patients.
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